Skip to content

Exploring the Potential Mechanisms of Wuda Granules in Treating Postoperative Ileus in Patients with Colorectal Cancer Based on Transcriptome Sequencing

Exploring the Potential Mechanisms of Wuda Granules in Treating Postoperative Ileus in Patients with Colorectal Cancer Based on Transcriptome Sequencing

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000265
Enrollment
Unknown
Registered
2025-02-14
Start date
2025-02-21
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Ileus

Interventions

Wuda Granules group:1.Basic treatment: Including antibiotic therapy, fluid support therapy, etc., and postoperative rapid recovery nursing management.2.Wuda Granules treatment.
Control group:Basic treatment: Including antibiotic therapy fluid support therapy etc. and postoperative rapid recovery nursing management.

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1)Patients undergoing elective laparoscopic-assisted bowel resection; 2)Age: 18 years = age = 80 years; 3)Gender: No gender restriction both male and female are eligible; 4)Individuals who have signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with malignant tumors requiring extended radical surgery or ostomy surgery; 2.Individuals with mental disorders who cannot cooperate; 3.Pregnant or breastfeeding women; 4.Patients with severe intestinal adhesions due to repeated abdominal surgeries; 5.Patients with intraoperative blood loss exceeding 400 mL or those requiring blood transfusion during surgery; 6.Patients who develop serious complications within 6 hours postoperatively or those transferred to the ICU after surgery; 7.Patients who must use medications or treatments that significantly affect gastrointestinal function postoperatively such as those requiring hyperthermic intraperitoneal chemotherapy; 8.Patients who are currently participating in or have participated in other clinical trials within the last month before this study; 9.Patients whom the investigator deems unsuitable for this clinical research.

Design outcomes

Primary

MeasureTime frame
the incidence rate of POI;

Secondary

MeasureTime frame
Bowel sounds return to normal time;Gene expression in normal tissue adjacent to colorectal cancer;First bowel movement time;Gastrointestinal symptom score;

Countries

China

Contacts

Public Contactjiangzhi

Guangdong Provincial Hospital of Traditional Chinese Medicine

2000jiangzhi@163.com15011937399

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026